Folate (Vitamin B9) for MTHFR Mutation

The short answer: if you have an MTHFR mutation, ordinary folic acid still works. Women with the TT genotype cut their homocysteine by 20% after 4 weeks on 400 mcg of folic acid a day in a German placebo-controlled trial, the largest fall of any genotype (Fohr 2002). The CDC says plainly that common variants such as C677T are not a reason to avoid folic acid.

The popular claim that carriers "can't use" folic acid and must take methylfolate is not what the trials show. Methylfolate raises plasma folate faster, but it has not beaten folic acid on homocysteine or any health outcome, and folic acid is still the only form proven in large trials to prevent neural tube defects (Skavinska 2026). The real limits are elsewhere: most data are blood markers, and the stroke benefit seen in China was not specific to TT carriers.

MTHFR makes 5-methyltetrahydrofolate (5-MTHF), the folate form that recycles homocysteine into methionine. NIH's Office of Dietary Supplements notes that people with the 677C>T variant have a reduced ability to make 5-MTHF because the enzyme is less active. The practical effect is modest: in a meta-analysis of 40 studies, women with TT had 13% lower serum folate and 16% lower red blood cell folate than women with CC (Tsang 2015).

That gap depends on diet. In Asian populations with low folate intake, TT carriers' homocysteine was 3.12 umol/L higher than CC carriers'; in fortified America, Australia and New Zealand the gap was 0.13 umol/L, essentially nothing (Holmes 2011). Enough folate overrides most of the genetic effect.

Methylfolate is already in the 5-MTHF form, so it bypasses the slower enzyme. In a crossover study of 24 women, a single 416 mcg dose of [6S]-5-MTHF produced a higher and faster plasma folate peak than 400 mcg of folic acid in both TT and CC women, and unmetabolised folic acid appeared in plasma regularly after folic acid but rarely after methylfolate (Prinz-Langenohl 2009).

But a faster peak after one dose is not a better outcome. The same research group's 8-week trial found folic acid lowered homocysteine at least as well as methylfolate in every genotype (Fohr 2002). The bypass argument is plausible on paper; the trials have not turned it into a measurable benefit.

The doses that worked in carriers are ordinary ones. Fohr's trial used 400 mcg of folic acid or 480 mcg of methylfolate a day for 8 weeks. In 480 Chinese adults with hypertension, 800 mcg of folic acid cut homocysteine by 22.0% in TT carriers versus 10.8% in CC carriers, while 400 mcg gave similar falls in both (11.2% vs 9.9%) (Qin 2012).

Very low doses fall short. In a 932-woman trial, 100 mcg a day did not reduce high homocysteine in TT carriers, and TT carriers kept lower folate than CC carriers even at 4,000 mcg a day (Crider 2011). Going higher does not erase the gap, so there is no reason to megadose. NIH sets the upper limit for folic acid from supplements and fortified foods at 1,000 mcg a day for adults, including in pregnancy; food folate has no limit.

Three randomised trials agree. Fohr 2002 (160 women, double-blind, placebo-controlled) found folic acid cut homocysteine by at least 13% in all three genotypes, with the largest fall, 20%, in TT women. Qin 2012 showed TT carriers responded more than CC carriers to 800 mcg a day. In 272 Greek adults with homocysteine of 10 umol/L or more, both folinic acid and l-methylfolate lowered homocysteine over 3 months, TT carriers fell most, and the two forms did not differ (Mazokopakis 2023).

Pooling ten intervention studies, Colson 2017 found TT carriers started with homocysteine 2.7 umol/L higher than other genotypes, but after at least 4 weeks of supplementation the difference was no longer significant. A small 6-month trial of a methylfolate, vitamin B6 and methylcobalamin combination in 54 carriers lowered homocysteine 30.0% more than placebo, by 48.3% in homozygous carriers (Pokushalov 2024); because it was a three-vitamin product, it can't isolate methylfolate's share.

In a 142-person crossover trial, 400 mcg of folic acid a day raised red blood cell folate within each C677T genotype over 12 weeks (Anderson 2013). Crider 2011's large Chinese trial found TT carriers had lower plasma and red cell folate at every dose tested, up to 4,000 mcg a day, and genotype did not interact with dose.

So carriers respond, from a slightly lower baseline. The CDC's reading of the same evidence is that intake matters more than genotype for blood folate, and that 400 mcg a day raises blood folate whatever your genotype.

The CSPPT trial randomised 20,702 Chinese adults with hypertension, stratified by MTHFR genotype, to enalapril with or without 0.8 mg of folic acid. Over a median 4.5 years, folic acid lowered first stroke (2.7% vs 3.4%; HR 0.79, 95% CI 0.68-0.93) (Huo 2015). A later analysis reported a significant benefit in CC/CT carriers with high homocysteine (HR 0.73, 95% CI 0.55-0.97) and did not report a TT-specific benefit (Zhao 2017).

Outside low-folate settings the picture is flatter. A Lancet meta-analysis of 13 homocysteine-lowering trials found no clear stroke reduction (RR 0.94, 95% CI 0.85-1.04), mostly in populations with fortified food (Holmes 2011). For pregnancy, no trial has tested folate by MTHFR genotype; the advice to take 400 mcg of folic acid daily rests on folic acid's proven effect in all women, and a review of the genotype data called the extra-risk evidence for TT carriers inconsistent (Reilly 2014).

No trial has shown that MTHFR carriers get a health benefit from folate that non-carriers don't. No trial has compared methylfolate with folic acid on a clinical outcome such as stroke, miscarriage or birth defects. And the American College of Medical Genetics concluded that MTHFR testing has minimal clinical utility and should not be ordered as part of a routine thrombophilia work-up (Hickey 2013).

At the doses studied, folate is well tolerated: CSPPT found no significant difference in adverse events between enalapril with 0.8 mg of folic acid and enalapril alone over a median 4.5 years (Huo 2015). The CDC notes folic acid at recommended amounts has not been shown to cause harm, and that more than the recommended amount is not better for preventing neural tube defects.

The main risk is hiding a vitamin B12 deficiency. NIH explains that large amounts of folate can correct the anaemia of B12 deficiency but not its nerve damage, which is why the upper limit for supplemental folic acid is 1,000 mcg a day. A 2026 review argues methylfolate carries less risk of masking B12 deficiency (Skavinska 2026), but NIH's warning covers large amounts of folate generally, so check B12 before any high dose.

Folate interacts with a few common medicines. NIH lists methotrexate as a folate antagonist, and notes that folate supplements might reduce blood levels of antiepileptic drugs such as phenytoin, carbamazepine and valproate, so people taking them should check with their clinician first.